Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Spessotto, Caroline Vieira; Cavalli, Hanaie; Eboni, Audred Cristina Biondo; Machado, Rafael Berlezi; Mousquer, Analara Munardi; Palazzo, Lara Both; Finkelsztejn, Alessandro; Goncalves, Marcus Vinicius Magno; Sato, Henry Koiti; Siquineli, Fabio; Fragoso, Yara Dadalti

doi:10.1590/0004-282X20160091

home Sumário navigate_before Anterior Atual Seguinte navigate_next

home Sumário

ARTICLES • Arq. Neuro-Psiquiatr. 74 (8) • Aug 2016 • https://doi.org/10.1590/0004-282X20160091 linkcopy

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Satisfação e pontos de vista dos pacientes com esclerose múltipla em tratamento com drogas modificadoras da doença

Authorship SCIMAGO INSTITUTIONS RANKINGS

ABSTRACT

Objective The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients’ satisfaction with the treatment must be taken into consideration.

Methods Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs.

Results One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability.

Conclusion Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.

multiple sclerosis; glatiramer acetate; interferon-beta; natalizumab; fingolimod hydrochloride

Statments	1 / 2 (disagree) (%)	3 (neutral) (%)	4 / 5 (agree) (%)
I feel that my treatment gives me benefits	4.5	10.8	84.7
I feel capable of administering the medication to myself	9.8	6.4	83.8
I feel that my MS symptoms have improved with treatment	13.3	11.5	75.2
After starting my treatment. I feel that my general health is good	11.7	8.0	80.3
I feel that many of my symptoms are under control with treatment	8.6	12.8	78.6
I believe the treatment is efficient	3.9	8.3	87.8
My present treatment gives me more benefits than did the previous one	13.8	17.8	68.4
The adverse events of this treatment negatively influence my physical performance	47.7	9.2	43.1
The adverse events of this treatment negatively influence my mental performance	63.6	10.2	26.2
I think this medication is easy to use	53.7	8.5	37.8
This treatment does not interfere with my daily activities	19.1	5.5	75.4
I follow the recommendations regarding therapy	7.6	1.8	90.6
I feel embarrassed if someone sees me taking the medication	69.7	8.0	22.3
I accept the limitations of this treatment	2.3	8.8	88.9
I believe the medication is good for me	3.3	4.3	92.4
The medication has more good aspects than bad ones	3.7	4.6	91.7
My quality of life has improved	8.1	15.3	76.6
The medication has a negative influence in my family life	73.1	9.0	17.9
The medication has a negative influence in my social life	63.2	6.9	29.9
I am in general satisfied with my treatment	9.3	5.4	85.3
I would recommend people to treat their MS	6.4	4.3	89.3
I believe the medication is efficient	3.8	5.5	90.7
I feel motivated to continue my treatment	5.0	4.1	90.9

Variable	Total group (n = 128)	Glatiramer acetate (n = 47)	Interferon beta (n = 36)	Natalizumab (n = 7)	Fingolimod (n = 28)
DMD switching	n = 54	n = 17 (36.25%)	n = 27 (57.4%)	n = 0	n = 0
Positive view on the benefit of treatment – %	82.1	81.5	83.5	76.2	87.2
Positive view on the convenience of use – %	86.3	86.8	84.2	85.7	90.8
Positive view on the tolerability – %	59.9	52.7	56.5	62.5	74.1
Overall satisfaction with DMD – %	83.8	87.9	80.2	85.7	90
Satisfaction after changing from another DMD – %	69.0	66.7	66.7	71.4	70.4

vertical_align_top show_chart

more_horiz close
- image
- translate
- link
- article
- vertical_align_top
- file_download
- show_chart
- image
- translate
- link
- article

location_on

Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org

rss_feed Acompanhe os números deste periódico no seu leitor de RSS

[TFN1] MS: multiple sclerosis.